Ionis Pharmaceuticals (IONS) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 11/02/23
Ionis shares significant business and pipeline progress at Innovation Day, highlighting strength of capabilities from research and technology through commercializationPRNewsWire • 10/04/23
Eplontersen Phase 3 results published in JAMA show consistent and sustained benefitPRNewsWire • 09/28/23
Strength Seen in Ionis Pharmaceuticals (IONS): Can Its 8.5% Jump Turn into More Strength?Zacks Investment Research • 09/27/23
Ionis enters agreement with Roche for two novel RNA-targeted programs for Alzheimer's disease and Huntington's diseasePRNewsWire • 09/27/23
Ionis announces positive olezarsen topline results from Phase 3 study in people with familial chylomicronemia syndromePRNewsWire • 09/26/23
Why Is Ionis Pharmaceuticals (IONS) Up 1.4% Since Last Earnings Report?Zacks Investment Research • 09/08/23
Ionis Pharmaceuticals: Mid-Sized Pharma Is A Strong Buy Opportunity For All-ComersSeeking Alpha • 09/07/23
Ionis Pharmaceuticals (IONS) Reports Q2 Results: What Key Metrics Have to Say (Revised)Zacks Investment Research • 08/10/23
Ionis Pharmaceuticals (IONS) Q2 Earnings and Revenues Surpass Estimates (Revised)Zacks Investment Research • 08/10/23
Ionis Pharmaceuticals (IONS) Reports Q2 Earnings: What Key Metrics Have to SayZacks Investment Research • 08/09/23
Ionis Pharmaceuticals (IONS) Q2 Earnings and Revenues Surpass EstimatesZacks Investment Research • 08/09/23
Ionis enters collaboration to advance next generation program targeting Lp(a) for cardiovascular diseasePRNewsWire • 08/03/23